HK1205932A1 - Pharmaceutical formulation for bedwetting and method of use thereof - Google Patents

Pharmaceutical formulation for bedwetting and method of use thereof

Info

Publication number
HK1205932A1
HK1205932A1 HK15106440.6A HK15106440A HK1205932A1 HK 1205932 A1 HK1205932 A1 HK 1205932A1 HK 15106440 A HK15106440 A HK 15106440A HK 1205932 A1 HK1205932 A1 HK 1205932A1
Authority
HK
Hong Kong
Prior art keywords
bedwetting
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
HK15106440.6A
Other languages
English (en)
Chinese (zh)
Inventor
．迪爾 大衛．
Original Assignee
Wellesley Pharmaceuticals Llc
Dill David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed by Wellesley Pharmaceuticals Llc, Dill David filed Critical Wellesley Pharmaceuticals Llc
Publication of HK1205932A1 publication Critical patent/HK1205932A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15106440.6A 2012-07-27 2015-07-06 Pharmaceutical formulation for bedwetting and method of use thereof HK1205932A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/048627 WO2014018223A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for bedwetting and method of use thereof

Publications (1)

Publication Number Publication Date
HK1205932A1 true HK1205932A1 (en) 2015-12-31

Family

ID=49997724

Family Applications (4)

Application Number Title Priority Date Filing Date
HK15106440.6A HK1205932A1 (en) 2012-07-27 2015-07-06 Pharmaceutical formulation for bedwetting and method of use thereof
HK18110004.3A HK1250628A1 (zh) 2012-07-27 2015-07-06 用於遺尿的藥物製劑及其使用方法
HK18105893.7A HK1246203A1 (zh) 2012-07-27 2015-07-06 用於緩解尿頻的藥物製劑及其使用方法
HK15106439.9A HK1205931A1 (en) 2012-07-27 2015-07-06 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK18110004.3A HK1250628A1 (zh) 2012-07-27 2015-07-06 用於遺尿的藥物製劑及其使用方法
HK18105893.7A HK1246203A1 (zh) 2012-07-27 2015-07-06 用於緩解尿頻的藥物製劑及其使用方法
HK15106439.9A HK1205931A1 (en) 2012-07-27 2015-07-06 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Country Status (16)

Country Link
US (3) US20160022615A1 (xx)
EP (3) EP2877179A4 (xx)
JP (4) JP2015522658A (xx)
KR (2) KR20150048741A (xx)
CN (4) CN104470522A (xx)
AU (3) AU2013293489B2 (xx)
BR (2) BR112015001627A2 (xx)
CA (2) CA2875818A1 (xx)
HK (4) HK1205932A1 (xx)
IL (3) IL236028A0 (xx)
MX (2) MX2015001190A (xx)
MY (1) MY171526A (xx)
RU (3) RU2015106672A (xx)
SG (2) SG11201500578VA (xx)
WO (2) WO2014018222A1 (xx)
ZA (2) ZA201408993B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526441A (ja) * 2015-09-01 2018-09-13 ウェルズリー ファーマスーティカルズ、エルエルシー 延長、遅延および即時放出製剤、ならびにその製造および使用方法
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING THE FREQUENCY OF MICTION, METHOD FOR MANUFACTURING AND USE THEREOF
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
JP2021506334A (ja) * 2017-11-07 2021-02-22 ポビバ コーポレーションＰｏｖｉｖａ Ｃｏｒｐ． Ｐｄｅ５阻害剤を含む食品及び飲料組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100618234B1 (ko) * 1998-12-23 2006-09-01 알자 코포레이션 다공성 입자를 포함하는 제형
WO2001017479A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
BR0113644A (pt) * 2000-08-30 2003-07-29 Lilly Icos Llc Usos do inibidor de pde5 no tratamento de enxaqueca
US20040259912A1 (en) * 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
EP1476146A1 (en) * 2002-02-19 2004-11-17 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
WO2004043365A2 (en) * 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
JP5451613B2 (ja) * 2007-08-06 2014-03-26 アラーガン、インコーポレイテッド デスモプレシン薬物送達のための方法及びデバイス
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
CN104540505A (zh) 2015-04-22
MX2015001190A (es) 2015-05-07
HK1246203A1 (zh) 2018-09-07
IL236622A0 (en) 2015-02-26
BR112015001627A2 (pt) 2017-07-04
KR20150048741A (ko) 2015-05-07
ZA201500459B (en) 2016-09-28
CA2879640A1 (en) 2014-01-03
KR20150048740A (ko) 2015-05-07
CN107335057A (zh) 2017-11-10
MY171526A (en) 2019-10-16
SG11201500601QA (en) 2015-04-29
AU2013293489A1 (en) 2015-03-12
JP2018039831A (ja) 2018-03-15
HK1250628A1 (zh) 2019-01-11
AU2013293488B2 (en) 2018-05-17
AU2013293488A2 (en) 2015-02-26
CN107661326A (zh) 2018-02-06
JP2015522658A (ja) 2015-08-06
US20170100351A1 (en) 2017-04-13
AU2013293488A1 (en) 2015-02-19
WO2014018222A1 (en) 2014-01-30
IL261232A (en) 2018-10-31
IL236028A0 (en) 2015-01-29
SG11201500578VA (en) 2015-03-30
WO2014018223A1 (en) 2014-01-30
HK1205931A1 (en) 2015-12-31
CA2875818A1 (en) 2014-01-30
AU2013293489B2 (en) 2017-09-07
RU2015106762A (ru) 2016-09-20
CN104470522A (zh) 2015-03-25
US20180344674A1 (en) 2018-12-06
RU2019101864A (ru) 2019-03-11
EP2877179A4 (en) 2016-03-02
EP2844241A1 (en) 2015-03-11
ZA201408993B (en) 2016-09-28
AU2018208765A1 (en) 2018-08-16
RU2015106672A (ru) 2016-09-20
EP2877179A1 (en) 2015-06-03
BR112014031306A2 (pt) 2017-06-27
US20160022615A1 (en) 2016-01-28
JP2018127482A (ja) 2018-08-16
EP3527204A1 (en) 2019-08-21
JP2015522659A (ja) 2015-08-06
EP2844241A4 (en) 2015-04-29
MX2015001188A (es) 2015-05-07

Similar Documents

Publication Publication Date Title
HK1255336A1 (zh) 藥物製劑及其製備方法
IL252566B (en) Pharmacy preparations and methods
EP2751086A4 (en) KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL231270A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceuticals containing them and methods of use
ZA201403762B (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
PL2814463T3 (pl) Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
HK1203149A1 (en) Novel dosage form and formulation of abediterol
IL261232A (en) A pharmaceutical formulation for reducing urinary frequency and a method for its use
IL231505B (en) Pharmaceutical preparation and method for its production
IL233961B (en) The composition of a phytogenic supplement and methods of its use
GB201208315D0 (en) Pharmaceutical methods and compositions
HRP20180781T1 (hr) Farmaceutski pripravak koji sadržava lidipidipin i proces pripreme
IL234614B (en) Pharmaceutical composition and preparation method thereof
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
GB201219328D0 (en) Game system and method of use thereof